ProKidney (PROK) Expected to Announce Quarterly Earnings on Thursday

ProKidney (NASDAQ:PROK) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.

ProKidney Stock Down 5.3 %

Shares of NASDAQ PROK opened at $0.99 on Thursday. ProKidney has a twelve month low of $0.94 and a twelve month high of $4.44. The firm has a market cap of $288.66 million, a P/E ratio of -1.80 and a beta of 1.38. The company has a 50 day moving average of $1.53 and a 200 day moving average of $1.79.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.